Evaluation of Danirixin (GSK1325756) Inhibition of CD11b Cell Surface Expression
Status:
Completed
Trial end date:
2015-07-02
Target enrollment:
Participant gender:
Summary
This study is to determine danirixin (GSK1325756) concentrations required to inhibit
neutrophil activation in blood obtained from Respiratory Syncytial Virus (RSV)-infected
children <2 years and healthy adults. The study will evaluate differences in neutrophil
activation between RSV-infected children <2 years and healthy adults with escalating
concentrations of Chemokine (C-X-C motif) Ligand 1 (CXCL1) and danirixin to determine if
RSV-infected children and adult neutrophils are similarly activated by CXCL1 and inhibited by
danirixin. This study will guide dose prediction to inhibit specific percentages of
neutrophils in future pediatric RSV-infection studies. This single-center, in vitro study
will consist of 2 parts. Approximately 24 subjects will be enrolled, including 12 healthy
adults and 12 RSV-infected children <2 years.